In advancing new therapeutics, Flexion is set apart by:
The commitment to develop and commercialize therapies that constitute more effective safer treatments of OA, a disease of epidemic proportions. Currently marketed treatments for OA provide limited benefit and many of these therapies carry serious safety liability. Flexion is developing new therapies that constitute substantial advances in the treatment of osteoarthritis (OA).
A diversified portfolio of novel, intra-articular (IA) therapies. Flexion is developing three novel drug candidates each of which represents a distinct mechanism of action. Together, these products have the potential to treat mild, moderate and severe forms of the disease and to slow disease progression.
Optimization of therapeutic effect with sited delivery — local, sustained delivery of drug to the site of disease. Local delivery and sustained release ensure prolonged local therapeutic concentrations and vanishingly low systemic exposures.
Deep expertise in all phases of drug development. We begin with the needs of patients, identify promising, differentiated drug candidates and design compact development plans with exacting attention to the expectations of regulators and payers.